AVROBIO (NASDAQ:AVRO) & Adaptive Biotechnologies (NASDAQ:ADPT) Head to Head Contrast
AVROBIO (NASDAQ:AVRO) & Adaptive Biotechnologies (NASDAQ:ADPT) Head to Head Contrast
Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) and AVROBIO (NASDAQ:AVRO – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
自適應生物科技(納斯達克：ADPT-GET評級)和AVROBIO(納斯達克：AVRO-GET評級)都是小盤醫療公司，但哪隻股票更好？我們將根據這兩家公司在分析師建議、估值、股息、風險、盈利能力、收益和機構持股方面的強弱進行對比。
Risk & Volatility
風險與波動性
Adaptive Biotechnologies has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
自適應生物科技公司的貝塔係數為0.96，這意味着其股價的波動性比標準普爾500指數低4%。相比之下，AVROBIO的貝塔係數為1.5，這意味着其股價的波動性比標準普爾500指數高50%。
Earnings and Valuation
收益和估值
This table compares Adaptive Biotechnologies and AVROBIO's revenue, earnings per share and valuation.
該表格比較了自適應生物技術公司和AVROBIO的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adaptive Biotechnologies | $154.34 million | 7.06 | -$207.28 million | ($1.64) | -4.65 |
| AVROBIO | N/A | N/A | -$119.13 million | ($2.72) | -0.32 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 適應性生物技術 | 1.5434億美元 | 7.06 | -2.0728億美元 | ($1.64) | -4.65 |
| AVROBIO | 不適用 | 不適用 | -1.1913億美元 | ($2.72) | -0.32 |
Analyst Recommendations
分析師建議
This is a breakdown of current ratings and recommmendations for Adaptive Biotechnologies and AVROBIO, as reported by MarketBeat.com.
據MarketBeat.com報道，這是對自適應生物技術和AVROBIO的當前評級和推薦的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adaptive Biotechnologies | 1 | 3 | 5 | 0 | 2.44 |
| AVROBIO | 0 | 2 | 4 | 0 | 2.67 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 適應性生物技術 | 1 | 3 | 5 | 0 | 2.44 |
| AVROBIO | 0 | 2 | 4 | 0 | 2.67 |
Adaptive Biotechnologies currently has a consensus price target of $22.29, indicating a potential upside of 192.08%. AVROBIO has a consensus price target of $5.29, indicating a potential upside of 509.59%. Given AVROBIO's stronger consensus rating and higher probable upside, analysts plainly believe AVROBIO is more favorable than Adaptive Biotechnologies.
自適應生物技術公司目前的一致目標價為22.29美元，表明潛在上漲192.08%。AVROBIO的共識目標價為5.29美元，表明潛在上漲509.59%。鑑於AVROBIO更高的共識評級和更高的可能上行空間，分析師顯然認為AVROBIO比自適應生物技術公司更有利。
Insider & Institutional Ownership
內部人與機構所有權
93.5% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 62.1% of AVROBIO shares are held by institutional investors. 4.2% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 6.4% of AVROBIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
自適應生物技術公司93.5%的股份由機構投資者持有。相比之下，AVROBIO 62.1%的股份由機構投資者持有。自適應生物技術公司4.2%的股份由公司內部人士持有。相比之下，AVROBIO 6.4%的股份由公司內部人士持有。強大的機構持股表明，對衝基金、大型基金管理公司和捐贈基金相信，一隻股票有望實現長期增長。
Profitability
盈利能力
This table compares Adaptive Biotechnologies and AVROBIO's net margins, return on equity and return on assets.
此表比較了自適應生物技術公司和AVROBIO的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Adaptive Biotechnologies | -145.37% | -39.90% | -25.93% |
| AVROBIO | N/A | -76.04% | -64.01% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 適應性生物技術 | -145.37% | -39.90% | -25.93% |
| AVROBIO | 不適用 | -76.04% | -64.01% |
Summary
摘要
AVROBIO beats Adaptive Biotechnologies on 7 of the 13 factors compared between the two stocks.
AVROBIO在兩隻股票比較的13個因素中有7個擊敗了自適應生物技術公司。
About Adaptive Biotechnologies
關於適應性生物技術
(Get Rating)
(獲取評級)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
自適應生物技術公司是一家商業階段的公司，開發了一個用於診斷和治療各種疾病的免疫藥物平臺。該公司提供免疫序列號，這是一個平臺和核心免疫測序產品，用於回答翻譯研究的問題，以及發現新的預後和診斷信號；以及T檢測冠狀病毒感染，用於確認過去的新冠肺炎感染。它還提供clonoSEQ，這是一種臨牀診斷產品，用於檢測和監測多發性骨髓瘤、B細胞急性淋巴細胞白血病和慢性淋巴細胞白血病患者的微小殘留疾病，並可作為CLIA驗證的實驗室開發的測試用於其他淋巴癌患者；免疫SEQ T-MAP COVID，供疫苗開發商和研究人員測量T細胞對疫苗的免疫反應。此外，該公司還提供一系列臨牀產品和服務，用於診斷、監測和治療癌症、自身免疫性疾病和傳染病等疾病。它服務於生命科學研究、臨牀診斷和藥物發現應用。自適應生物技術公司與基因技術公司進行戰略合作，開發、製造新的抗原導向T細胞療法，並將其商業化，用於治療一系列癌症；微軟公司開發診斷測試，從一次血液測試中早期發現各種疾病。該公司前身為自適應TCR公司，並於2011年12月更名為自適應生物技術公司。自適應生物技術公司成立於2009年，總部設在華盛頓州西雅圖。
About AVROBIO
關於AVROBIO
(Get Rating)
(獲取評級)
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO，Inc.是一家臨牀階段的基因治療公司，開發基於慢病毒的體外基因療法，在全球範圍內治療單劑後的罕見疾病。它的基因療法使用從患者那裏收集的造血幹細胞，並用慢病毒載體進行修飾，以插入目標疾病中有缺陷的基因的功能副本。該公司的產品包括AVR-RD-01，一種治療法布里病的基因療法。該公司還在開發AVR-RD-02，這是治療1型高謝病的1/2期臨牀試驗；AVR-RD-03，用於治療龐貝病；AVR-RD-04，用於治療胱氨酸病；AVR-RD-05，用於治療亨特綜合徵；以及AVR-RD-06，處於臨牀前階段，用於治療3型高謝病。該公司成立於2015年，總部位於馬薩諸塞州劍橋市。
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《適應性生物技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收對自適應生物技術公司和相關公司的最新新聞和分析師評級的每日簡要摘要。